POmAb

POmAb (Prothrombin Open monoclonal Antibody) is a recombinant monoclonal antibody that selectively targets the open conformation of prothrombin by binding to its kringle-1 domain. Prothrombin exists in an equilibrium between closed and open conformations. By selectively binding to the open form, POmAb stabilizes this conformation and reduces its conversion to thrombin by the prothrombinase complex, thereby inhibiting thrombin generation. Developed by researchers at Saint Louis University, Harvard Medical School (Beth Israel Deaconess Medical Center), and the University of North Carolina, POmAb is being investigated as a novel, safe anticoagulant strategy that provides antithrombotic effects in vivo without causing excessive bleeding.

Other names

Prothrombin Open monoclonal Antibody